Carl Ola Landgren, MD, PhD
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed smoldering multiple myeloma (SMM) based on the IMWG Criteria10 including: * Serum M-protein ≥3 g/dL and/or BMPCs≥10 % (but \<60%) * Absence of anemia: hemoglobin \>10 g/dL * Absence of renal failure: serum creatinine \<2.0 mg/dL * Absence of hypercalcemia: Calcium \<10.5 mg/dL * Absence of lytic bone lesion on X-ray, CT, or positron emission tomography (PET)/CT and not more than 1 lesion on whole body MRI (NOTE: At the discretion of the Investigator, whole body CT or PET/CT may replace MRI in p…
Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Talquetamab will be administered per discretion of treating physician. Participants will receive the recommended dosage.
Daratumumab SC will be administered by subcutaneous (SC) injection per discretion of treating physician. Participants will receive the recommended dosage.
Arctuva estimate
Verify or correct the compensation shown for this listing.